"Osseointegrated implants have become a revolutionary treatment for routine and reliable achievement of tissue replacement. However, although dental implant can achieve a fair rate of survival, still, some of them fail. The risk for implant failures is not evenly distributed among patients, which indicates that there are biological, mechanical, or behavioral risk factors that can cause implant failure. Among biological risk factors, drugs taken by patients are of special interest, due to the fact that most implant patients are elder adults that are often polymedicated.The success of implants relies mainly on osseointegration, a direct functional and structural interlocking between implants and bone. The process of osseointegration around implants is similar to the biological events occurring during bone repair and fracture healing. Dysregulation of bone metabolism is known to have a negative impact on bone healing and implant osseointegration. Many of the patients receiving implant treatments are taking different kinds of medications. Some drugs interfere with biological processes involved in bone metabolism.We hypothesize that medications interfering with bone metabolism could influence implant survival. The aim of our research is to identify risk associated with implant failure. Some example of such drugs are antihypertensive medications, selective serotonin reuptake inhibitors (SSRIs), and proton pump inhibitors (PPIs), etc., which are commonly prescribed for patients suffering from highly prevalent conditions such as hypertension, depression, and gastric acid reflux, respectively. The impact of these drugs on osseointegration is unexplored and important to know whether they could affect bone, osseointegration, and dental implants. In fact, our research is looking into the relationship between pharmacology, osseointegration and dental implants. It also may help to open the door for new pharmacological innovation that might improve the success of osseointegrated implants, and avoid unnecessary complications. This research project is of great relevance in health care science in general, and in dentistry in particular, as well as for dental implant patients taking certain medications. Accordingly, we believe that this project is of great importance to healthcare researchers, practitioner and patients.The three retrospective cohort studies included a cohort of patients with osseointegrated dental implant placement at the East Coast Oral Surgery clinic in Moncton, Canada, from January 2007 to September 2015. Kaplan-Meier estimator was used to describe the hazard function of dental implant failure in terms of the use of SSRIs, antihypertensive drugs, and PPIs, respectively. Multilevel mixed effects parametric survival analyses were used to test the association between medication exposure and risk of implant failure adjusting for potential confounders. The findings suggest that treatment with SSRIs or PPIs may be associated with an increased risk of osseointegrated dental implant failure, whereas antihypertensive drugs usage is associated with higher survival rate of dental implants.The publication of "Selective Serotonin Reuptake Inhibitors and the Risk of Osseointegrated Implant Failure: A Cohort Study" has been the most-read article of 2014 in the Journal of Dental Research. This article has been downloaded 13763 times and cited 12 times, amongst the highest ever scored in this journal (ranked #13 of 1,118). Also, it was picked up by 11 news outlets, including the Wall Street Journal, RCI-Radio Canada International, ScienceDaily, McGill news.The publication of "Antihypertensive Medications and the Survival Rate of Osseointegrated Dental Implants: A Cohort Study" has been highlighted by Dentistry Today. " --